A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1

PURPOSE: Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. The treatment efficacy of osimertinib was assessed in previously untreated patients with metastatic non–small cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Cheol-Kyu, Cho, Hyun-Ju, Choi, Yoo-Duk, Oh, In-Jae, Kim, Young-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812005/
https://www.ncbi.nlm.nih.gov/pubmed/32972042
http://dx.doi.org/10.4143/crt.2020.459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812005/
https://www.ncbi.nlm.nih.gov/pubmed/32972042
http://dx.doi.org/10.4143/crt.2020.459

Ejemplares similares